Compound Global Advisors LLC Has $55,000 Position in Eli Lilly and Company $LLY

Compound Global Advisors LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 79.7% in the second quarter, Holdings Channel reports. The fund owned 71 shares of the company’s stock after selling 279 shares during the period. Eli Lilly and Company comprises approximately 5.0% of Compound Global Advisors LLC’s holdings, making the stock its 11th biggest position. Compound Global Advisors LLC’s holdings in Eli Lilly and Company were worth $55,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. WestEnd Advisors LLC lifted its holdings in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC bought a new stake in Eli Lilly and Company during the first quarter worth about $27,000. Citizens National Bank Trust Department increased its holdings in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company during the first quarter worth approximately $40,000. Finally, TD Capital Management LLC raised its stake in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after acquiring an additional 31 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 1.0%

LLY stock opened at $818.45 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The company has a market cap of $774.63 billion, a P/E ratio of 53.49, a PEG ratio of 1.18 and a beta of 0.47. The business has a fifty day moving average of $749.52 and a 200-day moving average of $766.23.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the business earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky acquired 1,000 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock worth $2,894,841 over the last 90 days. Insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft decreased their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. Berenberg Bank restated a “hold” rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. Finally, UBS Group reduced their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $939.12.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.